UTHR Share Price

Open 131.86 Change Price %
High 132.87 1 Day -0.11 -0.08
Low 130.76 1 Week 1.67 1.29
Close 131.59 1 Month 10.59 8.75
Volume 1195642 1 Year 29.48 28.87
52 Week High 169.89
52 Week Low 97.52
UTHR Important Levels
Resistance 2 133.55
Resistance 1 132.74
Pivot 131.74
Support 1 130.44
Support 2 129.63
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

United Therapeutics Corporation (NASDAQ: UTHR)

UTHR Technical Analysis 2
As on 23rd Jun 2017 UTHR Share Price closed @ 131.59 and we RECOMMEND Sell for LONG-TERM with Stoploss of 132.09 & Strong Buy for SHORT-TERM with Stoploss of 124.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
UTHR Target for June
1st Target up-side 125.08
2nd Target up-side 128.02
3rd Target up-side 130.96
1st Target down-side 116.7
2nd Target down-side 113.76
3rd Target down-side 110.82
UTHR Other Details
Segment EQ
Market Capital 2447069440.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.unither.com
UTHR Address
UTHR
1040 Spring Street
Silver Spring, MD 20910
United States
Phone: 301-608-9292
Fax: 301-608-9291
Interactive Technical Analysis Chart United Therapeutics Corporation ( UTHR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on United Therapeutics Corporation
UTHR Business Profile
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Adcirca, Monoclonal Antibodies (MAbs), Glycobiology Antiviral Agents, Cell-Based Therapy, and Engineered Lungs and Lung Tissue for Transplantation. Prostacyclin analogues are stable synthetic forms of prostacyclin. Its product is Remodulin (treprostinil) Injection (Remodulin). PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in cells. Its PDE-5 inhibitor product is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of pulmonary arterial hypertension (PAH). MAbs act by targeting tumor-associated antigens on cancer cells to activate a patient's immune system against the cancer cells.